Media Release

English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB) 

  • Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion)
    • Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with continued strong growth from Entresto (+34% cc), Zolgensma (+81% cc), and Cosentyx (+11% cc). Kesimpta sales reached USD 50 million
    • Oncology BU grew +1% (cc, +4% USD) driven by Kymriah (+55% cc), Promacta/Revolade (+13% cc), Kisqali (+19% cc) and Jakavi (+8% cc). …

The COVID-19 pandemic highlights the importance of robust health systems to respond to disease outbreaks and to control other deadly diseases such as malaria. On World Malaria Day, April 25, we are calling on the global health community to continue to uphold progress and commitments made in the fight to end malaria.

Follow us on social media at #MalariaFuture

  • SMART study to extend data beyond patient population studied in clinical trials
  • New clinical study to evaluate safety and efficacy of Zolgensma in children up to 21 kg, adding to real-world experience and regulatory approvals in Europe and Canada

Basel, April 23, 2021 — Novartis today announced plans to initiate SMART, a Phase 3b clinical study to evaluate the safety and efficacy of Zolgensma® (onasemnogene abeparvovec) in young children with spinal muscular atrophy (SMA) weighing ≥ 8.5 kg and ≤ 21 kg …

  • Kesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients with relapsing forms of multiple sclerosis (RMS) according to new post hoc data from the Phase III ASCLEPIOS trials, further supporting Kesimpta as a first-choice treatment option for adults with RMS1

  • More than 50% of confirmed disability worsening events in newly diagnosed, treatment-naïve RMS patients were PIRA, an emerging endpoint …
  • Initial agreement covers reservation of the large-scale state-of-the-art biologics facility in Singapore site for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
  • Follows recent initial agreements for providing manufacturing capacity for CureVac and BioNtech   

Basel, April 15, 2021 — Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche’s …

Today is World Chagas Disease Day. This celebration, the second in history, takes place against the backdrop of the COVID-19 pandemic which continues to disproportionately affect vulnerable populations around the world, including people affected by Chagas disease. Patients who have heart conditions caused by Chagas disease could be at higher risk of severe complications from COVID-19.

Considered by the World Health Organization as one of the 10 neglected tropical diseases, Chagas disease affects approximately 6 million people, mainly in Latin America – yet it has spread in recent …

Chagas disease affects approximately six million people, mainly in Latin America. The disease can be silent for decades until it may become fatal, leading to cardiovascular complications in up to 30% of patients. Like other neglected tropical diseases, Chagas disease often affects poor and marginalized communities.

For the second time in history, the global community officially celebrated World Chagas Disease Day in April 2021 to bring the disease to people’s attention. Discover the stories of people affected by Chagas disease.

Photographer Ana Ferreira travelled to Bolivia, …